For the year ending 2025-12-31, TOI made $502,729K in revenue. -$60,606K in net income. Net profit margin of -12.06%.
| Income Statement | 2025-12-31 | |||
|---|---|---|---|---|
| Total operating revenue | 502,729 | |||
| Direct costs-Health Care Patient Service | 205,502 | |||
| Direct costs-Health Care Specialty Pharmacy | 220,558 | |||
| Direct costs-Clinical Research Trials And Other Revenue | 234 | |||
| Selling, general and administrative expense | 105,574 | |||
| Depreciation and amortization | 6,944 | |||
| Total operating expenses | 538,812 | |||
| Loss from operations | -36,083 | |||
| Interest expense, net | 11,276 | |||
| Change in fair value of derivative warrant liabilities | 247 | |||
| Change in fair value of conversion option derivative liabilities | -12,206 | |||
| Other, net | -925 | |||
| Total other non-operating expense | -24,654 | |||
| Loss before provision for income taxes | -60,737 | |||
| Income tax benefit | -131 | |||
| Net loss | -60,606 | |||
| Basic EPS | -0.54 | |||
| Diluted EPS | -0.54 | |||
| Basic Average Shares | 92,389,381 | |||
| Diluted Average Shares | 92,389,381 | |||
Oncology Institute, Inc. (TOI)
Oncology Institute, Inc. (TOI)